Last reviewed · How we verify
Omexa Sublingual Sumatriptan tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Omexa Sublingual Sumatriptan tablet (Omexa Sublingual Sumatriptan tablet) — Targia Pharmaceuticals Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Omexa Sublingual Sumatriptan tablet TARGET | Omexa Sublingual Sumatriptan tablet | Targia Pharmaceuticals Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Omexa Sublingual Sumatriptan tablet CI watch — RSS
- Omexa Sublingual Sumatriptan tablet CI watch — Atom
- Omexa Sublingual Sumatriptan tablet CI watch — JSON
- Omexa Sublingual Sumatriptan tablet alone — RSS
Cite this brief
Drug Landscape (2026). Omexa Sublingual Sumatriptan tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/omexa-sublingual-sumatriptan-tablet. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing